Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guérin immunity

Journal of Immunology

Volumn 177, Issue 9, 2006, Pages 6353-6360

  Dietrich, Jes ^a   Andersen, Claire ^a   Rappuoli, Rino ^b   Doherty, T Mark ^a   Jensen, Charlotte Green ^a   Andersen, Peter ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b Statens Serum Institut ^*

Author keywords

[No Author keywords available]

Indexed keywords

AG85B ESAT 6 FUSION PROTEIN; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; HYBRID PROTEIN; LTK 63; PHOSPHORYL LIPID A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BCG VACCINATION; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; LUNG; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TUBERCULOSIS;

EID: 33750319222     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.9.6353     Document Type: Article

References (34)

1. Wang, J., L. Thorson, R. W. Stokes, M. Santosuosso, K. Huygen, A. Zganiacz, M. Hitt, and Z. Xing. 2004. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol 173: 6357-6365.
2. Giri, P. K., S. B. Sable, I. Verma, and G. K. Khuller. 2005. Comparative evaluation of intranasal and subcutaneous route of immunization for development of mucosal vaccine against experimental tuberculosis. FEMS Immunol. Med. Microbiol. 45: 87-93.
3. Barclay, W. R., W. M. Busey, D. W. Dalgard, R. C. Good, B. W. Janicki, J. E. Kasik, E. Ribi, C. E. Ulrich, and E. Wolinsky. 1973. Protection of monkeys against airborne tuberculosis by aerosol vaccination with bacillus Calmette-Guerin. Am. Rev. Respir. Dis. 107: 351-358.
4. Falero-Diaz, G., S. Challacombe, D. Banerjee, G. Douce, A. Boyd, and J. Ivanyi. 2000. Intranasal vaccination of mice against infection with Mycobacterium tuberculosis. Vaccine 18: 3223-3229.
5. Lyadova, I. V., H. M. Vordermeier, E. B. Eruslanov, S. V. Khaidukov, A. S. Apt, and R. G. Hewinson. 2001. Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFN-γ in their lungs. Clin. Exp. Immunol. 126: 274-279.
6. Chen, L., J. Wang, A. Zganiacz, and Z. Xing. 2004. Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect. Immun. 72: 238-246.
7. + T cells recognizing CFP10 are recruited to the lung after Mycobacterium tuberculosis infection. J. Exp. Med. 200: 1479-1489.
8. Santosuosso, M., X. Zhang, S. McCormick, J. Wang, M. Hitt, and Z. Xing. 2005. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen. J. Immunol. 174: 7986-7994.
9. Del Giudice, G., and R. Rappuoli. 1999. Genetically derived toxoids for use as vaccines and adjuvants. Vaccine 17(Suppl. 2): S44-S52.
10. Giuliani, M. M., G. Del Giudice, V. Giannelli, G. Dougan, G. Douce, R. Rappuoli, and M. Pizza. 1998. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 187: 1123-1132.
11. Pizza, M., M. M. Giuliani, M. R. Fontana, E. Monaci, G. Douce, G. Dougan, K. H. Mills, R. Rappuoli, and G. Del Giudice. 2001. Mucosal vaccines: nontoxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19: 2534-2541.
12. + T cell responses. J. Immunol. 166: 1106-1113.
13. Simmons, C. P., P. Mastroeni, R. Fowler, M. Ghaem-maghami, N. Lycke, M. Pizza, R. Rappuoli, and G. Dougan. 1999. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. J. Immunol. 163: 6502-6510.
14. Neidleman, J. A., M. Vajdy, M. Ugozzoli, G. Ott, and D. O'Hagan. 2000. Genetically detoxified mutants of heat-labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T-cell responses against HIV-1 gag-p55. Immunology 101: 154-160.
15. Marchetti, M., M. Rossi, V. Giannelli, M. M. Giuliani, M. Pizza, S. Censini, A. Covacci, P. Massari, C. Pagliaccia, R. Manetti, et al. 1998. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine 16: 33-37.
16. Tierney, R., A. S. Beignon, R. Rappuoli, S. Muller, D. Sesardic, and C. D. Partidos. 2003. Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses. J. Infect. Dis. 188: 753-758.
17. Baudner, B. C., M. Morandi, M. M. Giuliani, J. C. Verhoef, H. E. Junginger, P. Costantino, R. Rappuoli, and G. Del Giudice. 2004. Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system. J. Infect. Dis. 189: 828-832.
18. Bonenfant, C., I. Dimier-Poisson, F. Velge-Roussel, D. Buzoni-Gatel, G. Del Giudice, R. Rappuoli, and D. Bout. 2001. Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii. Infect. Immun. 69: 1605-1612.
19. Ryan, E. J., E. McNeela, G. A. Murphy, H. Stewart, D. O'Hagan, M. Pizza, R. Rappuoli, and K. H. Mills. 1999. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect. Immun. 67: 6270-6280.
20. Sterne, J. A., L. C. Rodrigues, and I. N. Guedes. 1998. Does the efficacy of BCG decline with time since vaccination? Int. J. Tuberc. Lung Dis. 2: 200-207.
21. Pine, S., J. Barackman, G. Ott, and D. O'Hagan. 2002. Intranasal immunization with influenza vaccine and a detoxified mutant of heat labile enterotoxin from Escherichia coli (LTK63). J. Control Release 85: 263-270.
22. Olsen, A. W., L. A. van Pinxteren, L. M. Okkels, P. B. Rasmussen, and P. Andersen. 2001. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect. Immun. 69: 2773-2778.
23. Olsen, A. W., A. Williams, L. M. Okkels, G. Hatch, and P. Andersen. 2004. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect. Immun. 72: 6148-6150.
24. Langermans, J. A., T. M. Doherty, R. A. Vervenne, T. van der Laan, K. Lyashchenko, R. Greenwald, E. M. Agger, C. Aagaard, H. Weiler, D. van Soolingen, et al. 2005. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23: 2740-2750.
25. Doherty, T. M., A. W. Olsen, J. Weischenfeldt, K. Huygen, S. D'Souza, T. K. Kondratieva, V. V. Yeremeev, A. S. Apt, B. Raupach, L. Grode, et al. 2004. Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosis. J. Infect. Dis. 190: 2146-2153.
26. Doherty, T. M., A. W. Olsen, L. van Pinxteren, and P. Andersen. 2002. Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis. Infect. Immun. 70: 3111-3121.
27. Andersen, P., and T. M. Doherty. 2005. The success and failure of BCG: implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 3: 656-662.
28. Dantas, O. M., R. A. Ximenes, F. de Albuquerque Mdeqq, N. L. da Silva, U. R. Montarroyos, W. V. de Souza, T. C. Pereira, A. R. Campelo, and L. C. Rodrigues. 2006. A case-control study of protection against tuberculosis by BCG revaccination in Recife, Brazil. Int. J. Tuberc. Lung Dis. 10: 536-541.
29. Olsen, A. W., P. R. Hansen, A. Holm, and P. Andersen. 2000. Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Eur. J. Immunol. 30: 1724-1732.
30. Flynn, J. L., J. Chan, K. J. Triebold, D. K. Dalton, T. A. Stewart, and B. R. Bloom. 1993. An essential role for interferon-γ in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178: 2249-2254.
31. Ladel, C. H., S. Daugelat, and S. H. Kaufmann. 1995. Immune response to Mycobacterium bovis bacille Calmette Guerin infection in major histocompatibility complex class I- and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance. Eur. J. Immunol. 25: 377-384.
32. Bowe, F., E. C. Lavelle, E. A. McNeela, C. Hale, S. Clare, B. Arico, M. M. Giuliani, A. Rae, A. Huett, R. Rappuoli, et al. 2004. Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin. Infect. Immun. 72: 4052-4060:
33. Brandt, L., J. Feino Cunha, A. Weinreich Olsen, B. Chilima, P. Hirsch, R. Appelberg, and P. Andersen. 2002. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun. 70: 672-678.
34. Rodrigues, L. C., S. M. Pereira, S. S. Cunha, B. Genser, M. Y. Ichihara, S. C. de Brito, M. A. Hijjar, I. Dourado, A. A. Cruz, C. Sant'Anna, et al. 2005. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 366: 1290-1295.